INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $29,394,000 | -1.7% | 514,956 | +5.4% | 0.48% | +29.7% |
| Q1 2022 | $29,889,000 | +169.1% | 488,460 | +79.5% | 0.37% | +149.7% |
| Q2 2021 | $11,109,000 | +50.9% | 272,140 | +25.4% | 0.15% | +34.9% |
| Q1 2021 | $7,361,000 | +41.6% | 216,955 | +32.7% | 0.11% | +29.8% |
| Q4 2020 | $5,200,000 | +103.4% | 163,518 | +64.1% | 0.08% | +61.5% |
| Q3 2020 | $2,557,000 | +775.7% | 99,644 | +454.7% | 0.05% | +420.0% |
| Q1 2017 | $292,000 | -92.0% | 17,964 | -80.8% | 0.01% | -92.2% |
| Q2 2016 | $3,631,000 | +42.3% | 93,536 | +1.9% | 0.13% | +55.4% |
| Q1 2016 | $2,552,000 | -54.0% | 91,796 | -11.0% | 0.08% | -55.6% |
| Q4 2015 | $5,548,000 | +56.5% | 103,147 | +16.5% | 0.19% | +46.1% |
| Q3 2015 | $3,546,000 | – | 88,561 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |